Exhibit 99.1

Contact: Investor Contact: Amedisys, Inc. David Castille Director, Treasury/Finance (225) 299-3391 david.castille@amedisys.com Media Contact: Amedisys, Inc. Kendra Kimmons Managing Director, Marketing & Communications (225) 299-3720 kendra.kimmons@amedisys.com

AMEDISYS REPORTS FOURTH QUARTER FINANCIAL RESULTS

AMEDISYS TO HOST CONFERENCE CALL TODAY AT 10:00 A.M. ET

BATON ROUGE, Louisiana (March 12, 2014) — Amedisys, Inc. (NASDAQ: AMED), a leading home health and hospice company, today reported its financial results for the fourth quarter and year ended December 31, 2013.

Three-Month Periods Ended December 31, 2013 and 2012

• After adding back for the 2013 period, $9.6 million ($5.9 million, net of income tax) or $0.19 per diluted share for certain items* and after adding back for the 2012 period $151.0 million ($112.5 million, net of income tax) or $3.71 per diluted share for the goodwill and other intangibles impairment charge and certain other items*, our adjusted results from continuing operations were as follows:

• Net service revenue of $303.5 million compared to $351.6 million in 2012, a decrease of $48.1 million or 13.7%.

• Net loss from continuing operations attributable to Amedisys, Inc. of $2.2 million compared to net income from continuing operations of $6.3 million in 2012, a decrease of 135.5%. (Net loss from continuing operations attributable to Amedisys, Inc. of $8.2 million compared to $106.2 million in 2012 on a GAAP basis.)

• Net loss from continuing operations attributable to Amedisys, Inc. per diluted share of $0.07 compared to net income from continuing operations attributable to Amedisys, Inc. of $0.21 per diluted share in 2012, a decrease of 133.3%. (Net loss from continuing operations attributable to Amedisys, Inc. per diluted share $0.26 compared to $3.50 per diluted share in 2012 on a GAAP basis.)

• Earnings before interest, taxes, depreciation and amortization attributable to continuing operations (“EBITDA”) of $6.8 million compared to $21.6 million in 2012, a decrease of 68.7%.

Twelve-Month Periods Ended December 31, 2013 and 2012

• After adding back for the 2013 period $158.2 million ($98.3 million, net of income tax) or $3.14 per diluted share for the U.S. Department of Justice settlement, proceeds from our D&O insurance and certain other items* and after adding back for the 2012 period $148.6 million ($110.1 million, net of income tax) or $3.67 per diluted share for the goodwill and other intangibles impairment charge and certain other items*, our adjusted results from continuing operations were as follows:

• Net service revenue of $1,249.3 million compared to $1,440.8 million in 2012, a decrease of $191.5 million or 13.3%.

• Net income from continuing operations attributable to Amedisys, Inc., of $5.2 million compared to $29.8 million in 2012, a decrease of 82.5%. (Net loss from continuing operations attributable to Amedisys, Inc. of $93.1 million compared to $80.3 million in 2012 on a GAAP basis.)

• Net income from continuing operations attributable to Amedisys, Inc. per diluted share of $0.16 compared to $0.99 per diluted share in 2012, a decrease of 83.8%. (Net loss from continuing operations attributable to Amedisys, Inc. per diluted share $2.98 compared to $2.68 per diluted share in 2012 on a GAAP basis.)

• EBITDA of $48.9 million compared to $97.3 million in 2012, a decrease of 49.7%.

Ronald A. LaBorde, Interim Chief Executive Officer stated, “While volumes were flat sequentially, our results for the quarter were below the guidance previously shared by the Company. An unexpected increase in employee healthcare costs contributed to the lower results.”

* See pages 10 & 11 for explanation of these certain items and the reconciliations of non-GAAP financial measures.

We urge caution in considering the current trends disclosed in this press release. The home health and hospice industry is highly competitive and subject to intensive regulations, and trends are subject to numerous factors, risks, and uncertainties, some of which are referenced in the cautionary language below and others that are described more fully in our reports filed with the Securities and Exchange Commission (“SEC”) including our Annual Report on Form 10-K for the fiscal year ended December 31, 2013, and subsequent Quarterly Reports on Form 10-Q, and current reports on Form 8-K which can be found on the SEC’s internet website, http://www.sec.gov, and our internet website, http://www.amedisys.com. We disclaim any obligations to update disclosed information on trends.

Earnings Call and Webcast Information

To participate in the conference call, please call a few minutes before 10:00 a.m. ET on Wednesday, March 12, 2014, to either (877) 512-9171 (Toll free) or (815) 573-0979 (Toll), use conference ID #40243209. A replay of the conference call will be available through March 19, 2014. The replay dial in number is (855) 859-2056 (Toll free) or (404) 537-3406 (Toll), use conference ID #40243209.

The call will also be available through our website and for seven days thereafter at the following web address: http://investors.amedisys.com.

We are headquartered in Baton Rouge, Louisiana. Our common stock trades on the NASDAQ Global Select Market under the symbol “AMED.”

Additional information

Our company website address is www.amedisys.com. We use our website as a channel of distribution for important company information. Important information, including press releases, analyst presentations and financial information regarding our company, is routinely posted on and accessible on the Investor Relations subpage of our website, which is accessible by clicking on the tab labeled “Investors” on our website home page. We also use our website to expedite public access to time-critical information regarding our company in advance of or in lieu of distributing a press release or a filing with the SEC disclosing the same information. Therefore, investors should look to the Investor Relations subpage of our website for important and time-critical information. Visitors to our website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations subpage of our website.

Forward-Looking Statements

When included in this press release, words like “believes,” “belief,” “expects,” “plans,” “anticipates,” “intends,” “projects,” “estimates,” “may,” “might,” “would,” “should” and similar expressions are intended to identify forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and uncertainties that could cause actual results to differ materially from those described therein. These risks and uncertainties include, but are not limited to the following: changes in Medicare and other medical payment levels, our ability to open care centers, acquire additional care centers and integrate and operate these care centers effectively, our ability to divest care centers currently held for sale, changes in or our failure to comply with existing Federal and State laws or regulations or the inability to comply with new government regulations on a timely basis, competition in the home health industry, changes in the case mix of patients and payment methodologies, changes in estimates and judgments associated with critical accounting policies, our ability to maintain or establish new patient referral sources, our ability to attract and retain qualified personnel, changes in payments and covered services due to the economic downturn and deficit spending by Federal and State governments, future cost containment initiatives undertaken by third-party payors, our access to financing due to the volatility and disruption of the capital and credit markets, our ability to meet debt service requirements and comply with covenants in debt agreements, business disruptions due to natural disasters or acts of terrorism, our ability to integrate and manage our information systems, our ability to agree on the terms of a settlement to resolve both the U.S. Department of Justice investigation and the Stark Law Self-Referral matter or fund required settlement payments in the manner currently contemplated and changes in law or developments with respect to any litigation or investigations relating the Company, including the SEC investigation, the OIG Self-Disclosure issues and various other matters, many of which are beyond our control.

Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on any forward-looking statement as a prediction of future events. We expressly disclaim any obligation or undertaking and we do not intend to release publicly any updates or changes in our expectations concerning the forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as required by law.

Non-GAAP Financial Measures

This press release includes the following non-GAAP financial measures as defined under SEC rules: EBITDA, defined as net loss from continuing operations attributable to Amedisys, Inc. before provision for income taxes, net interest expense and depreciation and amortization, adjusted EBITDA, defined as EBITDA excluding the accrual for the U.S. Department of Justice settlement, proceeds from our D&O insurance and certain other items*, adjusted net (loss) income from continuing operations attributable to Amedisys, Inc., defined as net loss from continuing operations attributable to Amedisys, Inc. excluding the accrual for the U.S. Department of

2

Justice settlement, proceeds from our D&O insurance and certain other items*, and adjusted net (loss) income from continuing operations attributable to Amedisys, Inc. per diluted share, defined as net loss from continuing operations attributable to Amedisys, Inc. common stockholders per diluted share excluding the accrual for the U.S. Department of Justice settlement, proceeds from our D&O insurance and certain other items*. In accordance with SEC rules, we have provided herein a reconciliation of these non-GAAP financial measures to the most directly comparable measures under GAAP. Management believes that these are useful gauges of our performance and are common measures used in our industry to assess relative financial performance among companies.

3

AMEDISYS, INC. AND SUBSIDIARIES

SELECT CONSOLIDATED FINANCIAL STATEMENT DATA AND SUPPLEMENTAL INFORMATION

(Amounts in thousands, except share, per share data and statistical information)

(Unaudited)

Balance Sheet Information

	As of December 31,
	2013			2012
ASSETS
Current assets:
Cash and cash equivalents	$	17,303		$	14,545
Patient accounts receivable, net of allowance for doubtful accounts of $14,231 and $20,994		111,133			169,172
Prepaid expenses		10,669			10,631
Deferred income taxes		55,329			—
Other current assets		10,785			11,440
Assets held for sale		60			—
Total current assets		205,279			205,788
Property and equipment, net of accumulated depreciation of $129,891, and $113,154		159,025			156,709
Goodwill		208,915			209,594
Intangible assets, net of accumulated amortization of $25,133 and $23,457		36,690			47,050
Deferred income taxes		90,214			92,804
Other assets, net		26,283			18,650
Total assets	$	726,406		$	730,595
LIABILITIES AND EQUITY
Current Liabilities:
Accounts payable	$	20,139		$	29,175
Accrued charge related to U.S. Department of Justice settlement		150,000			—
Payroll and employee benefits		70,801			79,341
Accrued expenses		57,572			54,855
Current portion of long-term obligations		13,904			35,807
Current portion of deferred income taxes		—			5,609
Total current liabilities		312,416			204,787
Long-term obligations, less current portion		33,000			66,904
Other long-term obligations		8,511			4,671
Total liabilities		353,927			276,362
Equity:
Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding		—			—
Common stock, $0.001 par value, 60,000,000 shares authorized; 33,413,970 and 31,876,508 shares issued; and 32,538,971 and 31,086,619 shares outstanding		33			32
Additional paid-in capital		467,890			450,792
Treasury stock at cost, 874,999 and 789,889 shares of common stock		(18,176	)		(17,116	)
Accumulated other comprehensive income		15			15
Retained earnings		(77,561	)		18,617
Total Amedisys, Inc. stockholders’ equity		372,201			452,340
Noncontrolling interests		278			1,893
Total equity		372,479			454,233
Total liabilities and equity	$	726,406		$	730,595

4

Statement of Operations Information

	For the Three-Month Periods Ended December 31,						For the Years Ended December 31,
	2013			2012			2013			2012
Net service revenue	$	303,497		$	351,586		$	1,249,344		$	1,440,836
Cost of service, excluding depreciation and amortization		179,336			198,899			717,996			810,704
General and administrative expenses:
Salaries and benefits		73,806			81,337			302,564			327,111
Non-cash compensation		1,586			1,152			6,519			7,217
Other		41,457			46,921			164,991			182,345
Provision for doubtful accounts		3,445			5,291			15,882			21,011
Depreciation and amortization		8,565			9,845			36,871			39,200
U.S. Department of Justice settlement		—			—			150,000			—
Goodwill and other intangibles impairment charge		5,664			162,103			9,492			162,103
Operating expenses		313,859			505,548			1,404,315			1,549,691
Operating loss		(10,362	)		(153,962	)		(154,971	)		(108,855	)
Other (expense) income:
Interest income		14			13			54			65
Interest expense		(1,934	)		(6,095	)		(4,412	)		(12,116	)
Equity in earnings from equity investments		466			604			1,520			1,695
Miscellaneous, net		(1,740	)		3,635			4,334			3,934
Total other (expense) income, net		(3,194	)		(1,843	)		1,496			(6,422	)
Loss before income taxes		(13,556	)		(155,805	)		(153,475	)		(115,277	)
Income tax benefit		5,038			34,400			58,773			20,020
Loss from continuing operations		(8,518	)		(121,405	)		(94,702	)		(95,257	)
Discontinued operations, net of tax		(1,459	)		(602	)		(3,073	)		(3,326	)
Net loss		(9,977	)		(122,007	)		(97,775	)		(98,583	)
Net loss attributable to noncontrolling interests		349			15,195			1,597			14,995
Net loss attributable to Amedisys, Inc.	$	(9,628	)	$	(106,812	)	$	(96,178	)	$	(83,588	)
Basic and diluted earnings per common share:
Loss from continuing operations attributable to Amedisys, Inc. common stockholders	$	(0.26	)	$	(3.50	)	$	(2.98	)	$	(2.68	)
Discontinued operations, net of tax		(0.04	)		(0.02	)		(0.10	)		(0.11	)
Loss attributable to Amedisys, Inc. common stockholders	$	(0.30	)	$	(3.52	)	$	(3.08	)	$	(2.79	)
Weighted average shares outstanding		31,685			30,358			31,247			29,896
Amounts attributable to Amedisys, Inc. common stockholders:
Loss from continuing operations	$	(8,169	)	$	(106,210	)	$	(93,105	)	$	(80,262	)
Discontinued operations, net of tax		(1,459	)		(602	)		(3,073	)		(3,326	)
Net loss	$	(9,628	)	$	(106,812	)	$	(96,178	)	$	(83,588	)

5

Cash Flow and Days Revenue Outstanding, Net Information

	For the Three-Month Periods Ended December 31,						For the Years Ended December 31,
	2013			2012			2013			2012
Net cash provided by operating activities	$	8,401		$	15,628		$	102,263		$	69,494
Net cash used in investing activities		(11,002	)		(19,744	)		(46,458	)		(59,993	)
Net cash used in financing activities		(23,722	)		(20,445	)		(53,047	)		(42,960	)
Net (decrease) increase in cash and cash equivalents		(26,323	)		(24,561	)		2,758			(33,459	)
Cash and cash equivalents at beginning of period		43,626			39,106			14,545			48,004
Cash and cash equivalents at end of period	$	17,303		$	14,545		$	17,303		$	14,545
Days revenue outstanding, net (1)								32.1			41.5

(1) Our calculation of days revenue outstanding, net at December 31, 2013 and 2012 is derived by dividing our ending patient accounts receivable (i.e., net of estimated revenue adjustments and allowance for doubtful accounts) by our average daily net patient revenue for the three month-period ended December 31, 2013 and 2012, respectively.

Supplemental Information - Home Health

	For the Three-Month Periods Ended												For the Year Ended December 31, 2013
	March 31, 2013			June 30, 2013			September 30, 2013			December 31. 2013
Financial Information (in millions):
Medicare	$	212.6		$	204.6		$	193.5		$	193.1		$	803.8
Non-Medicare		49.4			45.9			43.3			45.3			183.9
Net service revenue		262.0			250.5			236.8			238.4			987.7
Cost of service		150.4			143.3			140.8			144.4			578.9
Gross margin		111.6			107.2			96.0			94.0			408.8
Other operating expenses		84.8			81.6			79.5			79.4			325.3
Operating income before impairment (1)	$	26.8		$	25.6		$	16.5		$	14.6		$	83.5
Key Statistical Data:
Medicare:
Same Store Volume (2)
Revenue		(8	)%		(10	)%		(12	)%		(11	)%		(10	)%
Admissions		2	%		0	%		(1	)%		(1	)%		0	%
Recertifications		(17	)%		(18	)%		(21	)%		(16	)%		(18	)%
Total (3):
Admissions		50,007			47,734			45,420			45,405			188,566
Recertifications		28,687			27,493			26,119			25,609			107,908
Completed Episodes		75,884			75,461			70,401			69,034			290,780
Visits		1,370,884			1,323,138			1,253,329			1,230,625			5,177,976
Average revenue per completed episode (4)	$	2,778		$	2,831		$	2,822		$	2,840		$	2,817
Visits per completed episode (5)		17.5			17.7			17.3			17.5			17.5
Non-Medicare (3):
Admissions		21,586			18,235			17,832			18,898			76,551
Recertifications		8,200			7,532			7,262			7,310			30,304
Visits		422,357			380,502			358,819			370,103			1,531,781
Total (3):
Cost per Visit	$	83.89		$	84.09		$	87.31		$	90.21		$	86.27
Visits		1,793,241			1,703,640			1,612,148			1,600,728			6,709,757

6

	For the Three-Month Periods Ended												For the Year Ended December 31, 2012
	March 31, 2012			June 30, 2012			September 30, 2012			December 31, 2012
Financial Information (in millions):
Medicare	$	233.1		$	231.3		$	226.9		$	224.0		$	915.3
Non-Medicare		56.8			61.5			62.9			55.6			236.8
Net service revenue		289.9			292.8			289.8			279.6			1,152.1
Cost of service		164.5			166.6			168.5			161.8			661.4
Gross margin		125.4			126.2			121.3			117.8			490.7
Other operating expenses		92.7			89.4			90.0			89.8			361.9
Operating income before impairment (1)	$	32.7		$	36.8		$	31.3		$	28.0		$	128.8
Key Statistical Data:
Medicare:
Same Store Volume (2)
Revenue		(8	)%		(9	)%		(5	)%		(7	)%		(7	)%
Admissions		(2	)%		2	%		1	%		1	%		0	%
Recertifications		(5	)%		(7	)%		(6	)%		(12	)%		(8	)%
Total (3):
Admissions		49,044			48,351			47,347			47,633			192,375
Recertifications		34,611			34,204			34,048			31,652			134,515
Completed Episodes		79,115			80,320			78,691			79,220			317,346
Visits		1,566,514			1,560,587			1,513,255			1,435,814			6,076,170
Average revenue per completed episode (4)	$	2,876		$	2,883		$	2,863		$	2,845		$	2,867
Visits per completed episode (5)		18.7			19.1			18.9			18.4			18.8
Non-Medicare (3):
Admissions		22,357			23,103			23,416			21,141			90,017
Recertifications		9,509			10,493			11,253			10,013			41,268
Visits		488,223			525,325			534,242			463,894			2,011,684
Total (3):
Cost per Visit	$	80.04		$	79.88		$	82.31		$	85.17		$	81.78
Visits		2,054,737			2,085,912			2,047,497			1,899,708			8,087,854

(1) Operating income of $9.9 million and $75.0 million on a GAAP basis for the quarter and year ended December 31, 2013, respectively. Operating loss of $133.5 million and $32.8 million for the quarter and the year ended December 31, 2012, respectively.

(2) Medicare revenue, admissions or recertifications growth is the percent increase (decrease) in our Medicare revenue, admissions or recertifications for the period as a percent of the Medicare revenue, admissions or recertifications of the prior period.

(3) Based on continuing operations for all periods presented.

(4) Average Medicare revenue per completed episode is the average Medicare revenue earned for each Medicare completed episode of care excluding the impact of sequestration.

(5) Medicare visits per completed episode are the home health Medicare visits on completed episodes divided by the home health Medicare episodes completed during the period.

7

Supplemental Information - Hospice

	For the Three-Month Periods Ended												For the Year Ended December 31, 2013
	March 31, 2013			June 30, 2013			September 30, 2013			December 31, 2013
Financial Information (in millions):
Medicare	$	62.8			61.6		$	60.6		$	61.4		$	246.4
Non-Medicare		3.8			3.8			3.9			3.7			15.2
Net service revenue		66.6			65.4			64.5			65.1			261.6
Cost of service		35.2			34.5			34.5			34.9			139.1
Gross margin		31.4			30.9			30.0			30.2			122.5
Other operating expenses		19.7			18.1			17.8			16.9			72.5
Operating income before impairment (1)	$	11.7			12.8		$	12.2		$	13.3		$	50.0
Key Statistical Data:
Same store Medicare revenue growth (2)		(5	)%		(12	)%		(13	)%		(8	)%		(9	)%
Hospice admits		4,957			4,655			4,352			4,371			18,335
Average daily census		5,071			5,006			4,917			4,866			4,964
Revenue per day	$	145.98			143.61		$	142.52		$	145.60		$	144.43
Cost of service per day	$	77.04			75.34		$	75.79		$	77.63		$	76.45
Average length of stay		103			99			98			98			100
	For the Three-Month Periods Ended												For the Year Ended December 31, 2012
	March 31, 2012			June 30, 2012			September 30, 2012			December 31, 2012
Financial Information (in millions):
Medicare	$	65.1		$	69.6		$	70.2		$	67.8		$	272.7
Non-Medicare		4.1			3.9			3.9			4.1			16.0
Net service revenue		69.2			73.5			74.1			71.9			288.7
Cost of service		36.3			37.8			38.1			37.1			149.3
Gross margin		32.9			35.7			36.0			34.8			139.4
Other operating expenses		17.6			18.9			20.2			20.5			77.2
Operating income before impairment (1)	$	15.3		$	16.8		$	15.8		$	14.3		$	62.2
Key Statistical Data:
Same store Medicare revenue growth (2)		17	%		22	%		13	%		3	%		13	%
Hospice admits		4,854			4,849			4,667			4,629			18,999
Average daily census		5,171			5,478			5,592			5,381			5,406
Revenue per day	$	147.05		$	147.31		$	144.10		$	145.24		$	145.89
Cost of service per day	$	77.00		$	75.68		$	73.97		$	74.85		$	75.34
Average length of stay		92			95			102			106			99

(1) Operating income of $12.2 million and $49.0 million on a GAAP basis for the quarter and year ended December 31, 2013, respectively. Operating income of $13.8 million and $61.7 million on a GAAP basis for the quarter and year ended December 31, 2012, respectively.

(2) Same store Medicare revenue growth is the percent increase in our Medicare revenue for the period as a percent of the Medicare revenue of the period.

8

Supplemental Information – Corporate
	For the Three-Month Periods Ended												For the Year Ended December 31, 2013
	March 31, 2013			June 30, 2013			September 30, 2013			December 31, 2013
Financial Information (in millions):
Depreciation and amortization	$	6.7		$	6.2		$	6.0		$	5.6		$	24.5
U.S. Department of Justice settlement		—			—			150.0			—			150.0
Other operating expenses		26.4			25.8			25.4			26.9			104.5
Operating loss	$	(33.1	)	$	(32.0	)	$	(181.4	)	$	(32.5	)	$	(279.0	)
	For the Three-Month Periods Ended												For the Year Ended December 31, 2012
	March 31, 2012			June 30, 2012			September 30, 2012			December 31, 2012
Financial Information (in millions):
Depreciation and amortization	$	6.2		$	6.0		$	5.8		$	6.5		$	24.5
Other operating expenses		28.1			31.6			25.8			27.8			113.3
Operating loss	$	(34.3	)	$	(37.6	)	$	(31.6	)	$	(34.3	)	$	(137.8	)

9

AMEDISYS, INC. AND SUBSIDIARIES

RECONCILIATION OF NON-GAPP FINANCIAL MEASURES TO GAAP FINANCIAL STATEMENTS

(Amounts in thousands)

(Unaudited)

Earnings From Continuing Operations Before Interest, Taxes, Depreciation and Amortization (“EBITDA”) and Adjusted EBITDA
	For the Three-Month Periods Ended December 31,						For the Years Ended December 31,
	2013			2012			2013			2012
Net loss attributable to Amedisys, Inc.	$	(9,628	)	$	(106,812	)	$	(96,178	)	$	(83,588	)
Less:
Discontinued operations, net of tax		(1,459	)		(602	)		(3,073	)		(3,326	)
Net loss from continuing operations attributable to Amedisys, Inc.		(8,169	)		(106,210	)		(93,105	)		(80,262	)
Add:
Provision for income taxes		(5,038	)		(34,400	)		(58,773	)		(20,020	)
Interest expense, net		1,920			6,082			4,358			12,051
Depreciation and amortization		8,565			9,845			36,871			39,200
EBITDA (1)		(2,722	)		(124,683	)		(110,649	)		(49,031	)
Add:
Certain items (2)		9,626			151,013			158,177			148,609
Debt fees (2)		(118	)		(4,681	)		(118	)		(4,681	)
Tax adjustments (2)		—			—			1,534			2,404
Adjusted EBITDA (GUIDANCE BASIS) (3)		6,786			21,649			48,944			97,301
Add:
Legal fees		862			2,404			5,431			8,494
Adjusted EBITDA (3)	$	7,648		$	24,053		$	54,375		$	105,795
Adjusted Net (Loss) Income From Continuing Operations Attributable to Amedisys, Inc. Reconciliation:
	For the Three-Month Periods Ended December 31,						For the Years Ended December 31,
	2013			2012			2013			2012
Net loss attributable to Amedisys, Inc.	$	(9,628	)	$	(106,812	)	$	(96,178	)	$	(83,588	)
Less:
Discontinued Operations, net of tax		(1,459	)		(602	)		(3,073	)		(3,326	)
Net loss from continuing operations attributable to Amedisys, Inc.		(8,169	)		(106,210	)		(93,105	)		(80,262	)
Add:
Certain items (2)		5,930			112,511			98,326			110,075
Adjusted net (loss) income from continuing operations attributable to Amedisys, Inc. (GUIDANCE BASIS) (4)		(2,239	)		6,301			5,221			29,813
Add:
Legal fees		531			1,433			3,345			4,990
Adjusted net (loss) income from continuing operations attributable to Amedisys, Inc. (4)	$	(1,708	)	$	7,734		$	8,566		$	34,803
Adjusted Net (Loss) Income From Continuing Operations Attributable to Amedisys, Inc. per Diluted Share:
	For the Three-Month Periods Ended December 31,						For the Years Ended December 31,
	2013			2012			2013			2012
Net loss attributable to Amedisys, Inc. common stockholders per diluted share	$	(0.30	)	$	(3.52	)	$	(3.08	)	$	(2.79	)
Less:
Discontinued operations, net of tax		(0.04	)		(0.02	)		(0.10	)		(0.11	)
Net loss from continuing operations attributable to Amedisys, Inc. common stockholders per diluted share		(0.26	)		(3.50	)		(2.98	)		(2.68	)
Add:
Certain items (2)		0.19			3.71			3.14			3.67
Adjusted net (loss) income from continuing operations attributable to Amedisys, Inc. common stockholders per diluted share (GUIDANCE BASIS) (5)		(0.07	)		0.21			0.16			0.99
Add:
Legal fees		0.02			0.04			0.11			0.16
Adjusted net (loss) income from continuing operations attributable to Amedisys, Inc. common stockholders per diluted share (5)	$	(0.05	)	$	0.25		$	0.27		$	1.15

(1) EBITDA is defined as net loss from continuing operations attributable to Amedisys, Inc. before provision for income taxes, net interest expense, and depreciation and amortization. EBITDA should not be considered as an alternative to, or more meaningful than, income before income taxes, cash flow from operating activities, or other traditional indicators of operating performance. This calculation of EBITDA may not be comparable to a similarly titled measure reported by other companies, since not all companies calculate this non-GAAP financial measure in the same manner.

(2) The following details the U.S. Department of Justice settlement, proceeds from our D&O insurance and certain other items for the three-months and years ended December 31, 2013 and 2012:

10

	For the Three-Month Period Ended December 31, 2013									For the Year Ended December 31, 2013
	(Income) Expense			Net			Diluted EPS			(Income) Expense			Net			Diluted EPS
U.S. Department of Justice settlement	$	—			—			—		$	150,000			93,878			3.00
Goodwill and other intangibles impairment charge		5,664			3,489			0.11			9,492			5,847			0.18
D&O proceeds		—			—			—			(5,530	)		(3,406	)		(0.11	)
Exit activity costs		2,313			1,425			0.05			3,882			2,391			0.08
Gain on sale of care centers		—			—			—			(779	)		(480	)		(0.01	)
Debt costs		966			595			0.02			966			595			0.02
Tax adjustment		—			—			—			(1,534	)		(1,534	)		(0.05	)
OIG self-disclosure		—			—			—			997			614			0.02
Sale of airplane		683			421			0.01			683			421			0.01
Total	$	9,626		$	5,930		$	0.19		$	158,177		$	98,326		$	3.14
	For the Three-Month Period Ended December 31, 2012									For the Year Ended December 31, 2012
	(Income) Expense			Net			Diluted EPS			(Income) Expense			Net			Diluted EPS
Goodwill and other intangibles impairment charge	$	162,103			125,130			4.12			162,103			125,130			4.17
Non-controlling interests portion of impairment charges		(14,874	)		(14,874	)		(0.49	)		(14,874	)		(14,874	)		(0.50	)
Exit activities related to continuing operations		2,707			1,613			0.05			2,707			1,590			0.05
Debt Costs		4,681			2,790			0.09			4,681			2,750			0.09
Lawsuit settlement		(3,604	)		(2,148	)		(0.06	)		(3,604	)		(2,117	)		(0.06	)
Tax adjustment		—			—			—			(2,404	)		(2,404	)		(0.08	)
Total	$	151,013		$	112,511		$	3.71		$	148,609		$	110,075		$	3.67

(3) Adjusted EBITDA is defined as net loss from continuing operations attributable to Amedisys, Inc. before provision for income taxes, net interest expense, depreciation and amortization excluding the U.S. Department of Justice settlement, proceeds from our D&O insurance and certain other items*. Adjusted EBITDA should not be considered as an alternative to, or more meaningful than, income before income taxes, cash flow from operating activities, or other traditional indicators of operating performance. This calculation of adjusted EBITDA may not be comparable to a similarly titled measure reported by other companies, since not all companies calculate this non-GAAP financial measure in the same manner.

(4) Adjusted net (loss) income from continuing operations attributable to Amedisys, Inc. is defined as net loss from continuing operations attributable to Amedisys, Inc. excluding the accrual for the U.S. Department of Justice settlement, proceeds from our D&O insurance and certain other items*. Adjusted net (loss) income from continuing operations attributable to Amedisys, Inc. should not be considered as an alternative to, or more meaningful than, income before income taxes, cash flow from operating activities, or other traditional indicators of operating performance. This calculation of adjusted net (loss) income from continuing operations attributable to Amedisys, Inc. may not be comparable to a similarly titled measure reported by other companies, since not all companies calculate this non-GAAP measure in the same manner.

(5) Adjusted net (loss) income from continuing operations attributable to Amedisys, Inc. common stockholders per diluted share is defined as diluted loss from continuing operations per share excluding the earnings per share effect of the accrual for the U.S. Department of Justice settlement, proceeds from our D&O insurance and certain other items*. Adjusted net (loss) income from continuing operations attributable to Amedisys, Inc. common stockholders per diluted share should not be considered as an alternative to, or more meaningful than, income before income taxes, cash flow from operating activities, or other traditional indicators or operating performance. This calculation of adjusted net (loss) income from continuing operations attributable to Amedisys, Inc. common stockholders per diluted share may not be comparable to a similarly titled measure reported by other companies, since not all companies calculate this non-GAAP financial measure in the same manner.

11